Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma
Kevin R. Murphy(Boys Town National Research Hospital), Mario Castro(University of Kansas Medical Center), John M. Fahrenholz, Joshua Jacobs(California Allergy and Asthma Medical Group), Leif Bjermer(Lund University), Yael Shalit(Teva Pharmaceuticals (Israel)), Margaret Garin(Teva Pharmaceuticals (Hungary)), James Zangrilli(Teva Pharmaceuticals (United States))
The Journal of Allergy and Clinical Immunology In Practice
November 1, 2017
Cited by 146
Related Papers
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
|New England Journal of Medicine|2018|1.9k
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
|Journal of Allergy and Clinical Immunology|2007|933
Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial
|American Journal of Respiratory and Critical Care Medicine|2009|686
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
|CHEST Journal|2016|426